2022 World Conference on Lung Cancer (ePosters)-EP16.01-013. The Diagnostic Accuracy of Tumor Mutational Burden in Advanced NSCLC: An Individual Patient Data Meta-Analysis

EP16.01-013. The Diagnostic Accuracy of Tumor Mutational Burden in Advanced NSCLC: An Individual Patient Data Meta-Analysis

Back to course

Pdf Summary

Researchers from the University of Palermo conducted a meta-analysis to compare the accuracy of tumor mutational burden (TMB) detection from plasma (bTMB) and tissue (tTMB) in patients with advanced non-small-cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs). The study included six clinical trials with a total of 751 patients. The results showed that the sensitivity of ctDNA (circulating tumor DNA) was 0.59 and the specificity was 0.85, with an area under the curve (AUC) of 0.83. The positive likelihood ratio (PLR) was 3.86 and the negative likelihood ratio (NLR) was 0.43. The researchers also found that there was no significant bias associated with the use of ctDNA for TMB detection. <br /><br />These findings suggest that bTMB could be an accurate method for detecting TMB and could play a role in the management of metastatic NSCLC. The study highlights the potential of liquid biopsy, specifically ctDNA testing, as a non-invasive alternative to tissue biopsy for assessing TMB status in patients undergoing ICI therapy. The results of this meta-analysis contribute to the growing body of evidence on TMB as a predictive biomarker and provide further support for the use of bTMB in clinical decision-making. However, further research is needed to fully understand the clinical implications of TMB and to establish standardized methods for its evaluation. This study emphasizes the importance of personalized medicine approaches in cancer treatment and the need for reliable biomarkers to guide therapeutic decisions.

Asset Subtitle

Maria La Mantia

Meta Tag

Speaker Maria La Mantia

Topic Tumour Biology and Biomarkers - Immune Biology & Immunotherapy

Keywords

University of Palermo

meta-analysis

tumor mutational burden

plasma

tissue

non-small-cell lung cancer

immune checkpoint inhibitors

ctDNA

liquid biopsy

predictive biomarker